These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. String Vessel Formation is Increased in the Brain of Parkinson Disease. Yang P; Pavlovic D; Waldvogel H; Dragunow M; Synek B; Turner C; Faull R; Guan J J Parkinsons Dis; 2015; 5(4):821-36. PubMed ID: 26444086 [TBL] [Abstract][Full Text] [Related]
3. Analysis of gene expression in Parkinson's disease: possible involvement of neurotrophic support and axon guidance in dopaminergic cell death. Bossers K; Meerhoff G; Balesar R; van Dongen JW; Kruse CG; Swaab DF; Verhaagen J Brain Pathol; 2009 Jan; 19(1):91-107. PubMed ID: 18462474 [TBL] [Abstract][Full Text] [Related]
4. Cell death mechanisms in Parkinson's disease. Jellinger KA J Neural Transm (Vienna); 2000; 107(1):1-29. PubMed ID: 10809400 [TBL] [Abstract][Full Text] [Related]
5. Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson's and Alzheimer's disease. Gellhaar S; Sunnemark D; Eriksson H; Olson L; Galter D Cell Tissue Res; 2017 Sep; 369(3):445-454. PubMed ID: 28466093 [TBL] [Abstract][Full Text] [Related]
6. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders. Tong J; Rathitharan G; Meyer JH; Furukawa Y; Ang LC; Boileau I; Guttman M; Hornykiewicz O; Kish SJ Brain; 2017 Sep; 140(9):2460-2474. PubMed ID: 29050386 [TBL] [Abstract][Full Text] [Related]
7. Degenerative ultrastructural changes observed in the neuropil of caudate nuclei from Parkinson's disease patients. Machado-Salas J; Ibarra O; Martinez Fong D; Cornejo A; Aceves J; Kuri J Stereotact Funct Neurosurg; 1990; 54-55():297-305. PubMed ID: 2080345 [TBL] [Abstract][Full Text] [Related]
8. Novel alpha-synuclein-immunoreactive proteins in brain samples from the Contursi kindred, Parkinson's, and Alzheimer's disease. Langston JW; Sastry S; Chan P; Forno LS; Bolin LM; Di Monte DA Exp Neurol; 1998 Dec; 154(2):684-90. PubMed ID: 9878203 [TBL] [Abstract][Full Text] [Related]
9. Neuronal complex I deficiency occurs throughout the Parkinson's disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage. Flønes IH; Fernandez-Vizarra E; Lykouri M; Brakedal B; Skeie GO; Miletic H; Lilleng PK; Alves G; Tysnes OB; Haugarvoll K; Dölle C; Zeviani M; Tzoulis C Acta Neuropathol; 2018 Mar; 135(3):409-425. PubMed ID: 29270838 [TBL] [Abstract][Full Text] [Related]
10. Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms? Jellinger KA J Neural Transm Suppl; 1999; 56():1-29. PubMed ID: 10370901 [TBL] [Abstract][Full Text] [Related]
11. Altered machinery of protein synthesis is region- and stage-dependent and is associated with α-synuclein oligomers in Parkinson's disease. Garcia-Esparcia P; Hernández-Ortega K; Koneti A; Gil L; Delgado-Morales R; Castaño E; Carmona M; Ferrer I Acta Neuropathol Commun; 2015 Dec; 3():76. PubMed ID: 26621506 [TBL] [Abstract][Full Text] [Related]
12. Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and Parkin-linked Parkinson's disease. Hu MT; Scherfler C; Khan NL; Hajnal JV; Lees AJ; Quinn N; Wood NW; Brooks DJ Mov Disord; 2006 Mar; 21(3):299-305. PubMed ID: 16211589 [TBL] [Abstract][Full Text] [Related]
13. Dendritic reorganisation in the basal forebrain under degenerative conditions and its defects in Alzheimer's disease. III. The basal forebrain compared with other subcortical areas. Arendt T; Brückner MK; Bigl V; Marcova L J Comp Neurol; 1995 Jan; 351(2):223-46. PubMed ID: 7699112 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease. Theisen F; Leda R; Pozorski V; Oh JM; Adluru N; Wong R; Okonkwo O; Dean DC; Bendlin BB; Johnson SC; Alexander AL; Gallagher CL Neuroimage Clin; 2017; 16():557-563. PubMed ID: 28971007 [TBL] [Abstract][Full Text] [Related]
15. Deep-brain stimulation associates with improved microvascular integrity in the subthalamic nucleus in Parkinson's disease. Pienaar IS; Lee CH; Elson JL; McGuinness L; Gentleman SM; Kalaria RN; Dexter DT Neurobiol Dis; 2015 Feb; 74():392-405. PubMed ID: 25533682 [TBL] [Abstract][Full Text] [Related]
16. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. Mogi M; Kondo T; Mizuno Y; Nagatsu T Neurosci Lett; 2007 Feb; 414(1):94-7. PubMed ID: 17196747 [TBL] [Abstract][Full Text] [Related]
17. Nerve growth factor receptor immunoreactivity within the nucleus basalis (Ch4) in Parkinson's disease: reduced cell numbers and co-localization with cholinergic neurons. Mufson EJ; Presley LN; Kordower JH Brain Res; 1991 Jan; 539(1):19-30. PubMed ID: 1849779 [TBL] [Abstract][Full Text] [Related]
18. Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation. Tong J; Ang LC; Williams B; Furukawa Y; Fitzmaurice P; Guttman M; Boileau I; Hornykiewicz O; Kish SJ Neurobiol Dis; 2015 Oct; 82():243-253. PubMed ID: 26102022 [TBL] [Abstract][Full Text] [Related]
19. MRI study of caudate nucleus volume in Parkinson's disease with and without dementia with Lewy bodies and Alzheimer's disease. Almeida OP; Burton EJ; McKeith I; Gholkar A; Burn D; O'Brien JT Dement Geriatr Cogn Disord; 2003; 16(2):57-63. PubMed ID: 12784028 [TBL] [Abstract][Full Text] [Related]